Sign In
Search Icon
Menu Icon


H-CORE also coordinates the acquisition and distribution of a broad variety of COVID-19 therapeutics to help reduce severe disease, hospitalizations, and deaths.

H-CORE’s approach to COVID-19 treatments is like filling a medicine cabinet—H-CORE does not rely on one type, or one brand, or one treatment. The federal government invested in and continues to distribute a variety of countermeasures including monoclonal antibodies, pre-exposure prevention therapies, and oral antivirals.

Today, H-CORE makes therapeutic products​ available—at no cost—to state and territorial health departments, community health centers, and Federal Retail Pharmacy Partners across the country including thousands of Test to Treat​ sites nationwide. Nearly 11 million therapeutic courses have been made available so far​ to partners.

By the Numbers

Monoclonal Antibody Therapy icon

Monoclonal Antibodies Courses Made Available

Oral Antiviral Courses icon

Oral Antiviral
Courses Made Available

Pre-Exposure Therapy icon​​

Pre-Exposure Therapy Courses Made Available




H-CORE: ​HHS Coordination Operations and Response Element​​